These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29096750)

  • 1. Clinical efficacy and mechanism of lymphoplasma exchange in the treatment of Guillain-Barre syndrome.
    Luo MC; Wang WF; Yin WF; Li Y; Li BJ; Duan WW; Zeng QM; Luo YB; Yang XS; Yang H
    Cell Mol Biol (Noisy-le-grand); 2017 Oct; 63(10):106-115. PubMed ID: 29096750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Guillain-Barré syndrome with Bifidobacterium infantis through regulation of T helper cells subsets.
    Shi P; Qu H; Nian D; Chen Y; Liu X; Li Q; Li Q; Wang C; Ye M; Ma B
    Int Immunopharmacol; 2018 Aug; 61():290-296. PubMed ID: 29908492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin.
    Hou HQ; Miao J; Feng XD; Han M; Song XJ; Guo L
    BMC Neurol; 2014 Oct; 14():202. PubMed ID: 25315010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome.
    Chi LJ; Wang HB; Zhang Y; Wang WZ
    J Neuroimmunol; 2007 Dec; 192(1-2):206-14. PubMed ID: 17997492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.
    Maddur MS; Rabin M; Hegde P; Bolgert F; Guy M; Vallat JM; Magy L; Bayry J; Kaveri SV
    Immunol Res; 2014 Dec; 60(2-3):320-9. PubMed ID: 25391612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum C3 complement levels predict prognosis and monitor disease activity in Guillain-Barré syndrome.
    Min YG; Ju W; Seo JW; Ha YE; Ban JJ; Kwon YN; Jeong HY; Shin JY; Kim SM; Hong YH; Kim SJ; Sung JJ
    J Neurol Sci; 2023 Jan; 444():120512. PubMed ID: 36462224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome.
    Ye Y; Li SL; Li YJ
    Transfus Med; 2015 Apr; 25(2):79-84. PubMed ID: 25515056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments.
    Li S; Jin T; Zhang HL; Yu H; Meng F; Concha Quezada H; Zhu J
    Mediators Inflamm; 2014; 2014():740947. PubMed ID: 24899787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain-Barré syndrome.
    Liang SL; Wang WZ; Huang S; Wang XK; Zhang S; Wu Y
    Immunopharmacol Immunotoxicol; 2012 Dec; 34(6):1039-46. PubMed ID: 22738814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barré syndrome.
    Sanjay R; Flanagan J; Sodano D; Gorson KC; Ropper AH; Weinstein R
    J Clin Apher; 2006 Jul; 21(2):105-10. PubMed ID: 16342192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced circulating CD4+CD25+ cell populations in Guillain-Barré syndrome.
    Pritchard J; Makowska A; Gregson NA; Hayday AC; Hughes RA
    J Neuroimmunol; 2007 Feb; 183(1-2):232-8. PubMed ID: 17239444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between serum low-density neutrophils and acute-onset and recurrent Guillain-Barré syndrome.
    Ren K; Yang A; Lu J; Zhao D; Bai M; Ding J; Wei T; Li H; Guo J
    Brain Behav; 2022 Jan; 12(1):e2456. PubMed ID: 34894104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [History of Guillain-Barré Syndrome].
    Kusunoki S
    Brain Nerve; 2015 Nov; 67(11):1295-303. PubMed ID: 26560944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study.
    Wang Y; Shang P; Xin M; Bai J; Zhou C; Zhang HL
    BMC Neurol; 2017 Nov; 17(1):200. PubMed ID: 29157205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.
    Davidson AI; Halstead SK; Goodfellow JA; Chavada G; Mallik A; Overell J; Lunn MP; McConnachie A; van Doorn P; Willison HJ
    J Peripher Nerv Syst; 2017 Mar; 22(1):4-12. PubMed ID: 27801990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS).
    Verma R; Chaudhari TS; Raut TP; Garg RK
    J Neurol Sci; 2013 Dec; 335(1-2):105-11. PubMed ID: 24064258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.
    Han RK; Cheng YF; Zhou SS; Guo H; He RD; Chi LJ; Zhang LM
    J Clin Immunol; 2014 Jan; 34(1):94-103. PubMed ID: 24217817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma exchange for Guillain-Barré syndrome.
    Raphaël JC; Chevret S; Hughes RA; Annane D
    Cochrane Database Syst Rev; 2001; (2):CD001798. PubMed ID: 11406009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma exchange for Guillain-Barré syndrome.
    Raphaël JC; Chevret S; Hughes RA; Annane D
    Cochrane Database Syst Rev; 2002; (2):CD001798. PubMed ID: 12076424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy.
    Maddur MS; Stephen-Victor E; Das M; Prakhar P; Sharma VK; Singh V; Rabin M; Trinath J; Balaji KN; Bolgert F; Vallat JM; Magy L; Kaveri SV; Bayry J
    J Neuroinflammation; 2017 Mar; 14(1):58. PubMed ID: 28320438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.